알림
뒤로

About

About

MTS COMPANY

Since 2020, MTS COMPANY has been at the forefront of developing cutting-edge AI-powered solutions for medical diagnosis and prediction, with a dedicated focus on oncology.


Driven by a commitment to conquering cancer, we specialize in developing sophisticated AI platforms that empower healthcare professionals in pathology and radiology.


By harnessing the power of artificial intelligence, we strive to enhance diagnostic accuracy, optimize treatment strategies, and ultimately improve patient outcomes and quality of life.

Meet Our Team

We are dedicated to developing better diagnostic and predictive solutions, striving to win the fight against cancer.

Heewon ChungCEO

Jaemyoung JangCTO

Jangwon SeoProject Manager

Eunha KimData Master

Our Partners

AiAlpa-Platform is the result of a powerful collaboration, developed and rigorously validated in conjunction with 12 leading university hospitals and over 100 board-certified pathologists, ensuring its clinical robustness and real-world applicability.

MTS Company is a leading company in the digital health sector, specializing in AI-based technology, offering highly effective AI-assisted cancer diagnosis and prediction solutions.

MTS COMPANY

Since 2020, MTS COMPANY has been at the forefront of developing cutting-edge AI-powered solutions for medical diagnosis and prediction, with a dedicated focus on oncology.


Driven by a commitment to conquering cancer, we specialize in developing sophisticated AI platforms that empower healthcare professionals in pathology and radiology.


By harnessing the power of artificial intelligence, we strive to enhance diagnostic accuracy, optimize treatment strategies, and ultimately improve patient outcomes and quality of life.

Meet Our Team

We are dedicated to developing better diagnostic and predictive solutions,
striving to win the fight against cancer

Our Partners

AiAlpa-Platform is the result of a powerful collaboration, developed and rigorously validated in conjunction with 12 leading university hospitals and over 100 board-certified pathologists, ensuring its clinical robustness and real-world applicability.

2024

2024.07

Selected as a Participating Company for CES 2025

Contract Signed and Solution Delivered for Mitosis Analysis and Diagnosis Solution (Gangnam CHA Hospital)

2024.03

Selected as a Contractor for the National IT Industry Promotion Agency's AI Voucher Support Project (Medical Division)

(Total Project Cost: 340 million KRW)

2023

2023.06

Selected as an Innovative Growth R&D Contractor by Jeonbuk Technopark

(Total Project Cost: 230 million KRW)

2023.03

Selected as a Contractor for the Development of an AI Prediction Model for Ovarian Cancer HRD Test Results by the National Cancer Center

(Total Project Cost: 900 million KRW)

2022

2022.11

Established Jeonbuk Branch (Located in Jeonju City)

2022.03

Conducted UN WHISLE Pilot Project

(Partners: UNFPA - Samsung Electronics - Yonsei Severance Hospital - MTS Company - AI Doctor): Mobile AI Colposcopy

2021

2021.12

Selected as a "First Penguin" Company by the Korea Credit Guarantee Fund

2021.05

Selected as a Contractor for the Development of a Digital Pathology AI Cancer Analysis Solution by the Ministry of Health and Welfare (Total Project Cost: 15 billion KRW)

2021.04

Selected as a Contractor for the 3rd AI Training Data Construction Project by the National Information Society Agency (Total Project Cost: 4.1 billion KRW)

2020

2020.12

Selected as a Contractor for the 2nd AI Training Data Construction Project by the National Information Society Agency (Total Project Cost: 2 billion KRW)

2020.05

Established Subsidiary AI Doctor Co., Ltd. (MTS Company + Physician Shareholders): Ophthalmology Diagnostic Services for Non-Ophthalmologists

2019

2019.01

Certified as a Technology Innovative Small and Medium Enterprise (Inno-Biz)

2018

2018.12

Maintained Investment from Korea Credit Guarantee Fund (300 million KRW) Established and Certified In-house Corporate Research Institute

2018.08

Completed Government Project for AI Chatbot under the Startup Promotion Agency's Startup-Leading University Program

2016

2016.08

Maintained Angel Investment (Wonki Ryu - 150 million KRW - Convertible Redeemable Preferred Shares)

2015

2015.12

Company Establishment

In The Moment That
Changes The World,
MTS Stands At The Center

MTS

MTS COMPANY | Biz Licence 513-88-00391

Tel. 02. 501. 1980 | help@mtsco.co.kr

Addr. 434, Samseong-ro, Gangnam-gu, Seoul, South Korea


Copyright ©️ MTS Company CO., LTD. All rights reserved.

In The Moment That Changes The World,
MTS Stands At The Center

MTS

MTS COMPANY | Biz Licence 513-88-00391

Tel. 02. 501. 1980 | help@mtsco.co.kr

Addr. 434, Samseong-ro, Gangnam-gu, Seoul, South Korea


Copyright ©️ MTS Company CO., LTD. All rights reserved.

Click to move to other product

↓